RxDoctor Payments Data

Brian Moloney, MD

Gastroenterology · Milwaukee, WINPI 1578775755

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $106 of the $137 with a category attached, or 77.7%. Ambu Inc. accounts for 77.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in WI, where the typical reported total is $253.

$137in general payments, 2019–2025

Across 2 payments — averaging $68.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ambu Inc.$106
  • Pfizer$30
$243,894in research payments, 2019–2025

Across 55 payments — averaging $4434.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$143K
  • Eli Lilly$63K
  • E.r. Squibb & Sons, L.L.C.$37K
  • Amgen$693

What the payments were for

  • Food & beverage$10678%
  • Education$3022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ambu Inc.1$106
Pfizer1$30

How this compares

$137 in reported general payments places this provider in the 35th percentile of 285 gastroenterology providers in Wisconsin.

See all gastroenterology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$123,081
Medicare patients
544
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab22$631,912
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres14$162,288
CreonLipase/Protease/Amylase43$109,888
XeljanzTofacitinib Citrate13$71,063
LinzessLinaclotide78$70,950
ZenpepLipase/Protease/Amylase15$44,993
DipentumOlsalazine Sodium13$24,815
Mesalamine ErMesalamine15$9,905
MovantikNaloxegol Oxalate12$8,185
Mesalamine45$8,167
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates126$7,907
Dexlansoprazole DrDexlansoprazole18$6,337
CholestyramineCholestyramine (With Sugar)31$5,613
Omeprazole266$5,395
Pantoprazole Sodium421$5,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$30$71,06313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 285 gastroenterology providers in Wisconsin.

Other gastroenterology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →